Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 14/20 | 0.65 |
| ▸ | AKR1C2 | P52895 | 14/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CDC42 | P60953 | 1/20 | 0.65 |
| ▸ | RAC1 | P63000 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.65 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11460825 | 1.00 | AKR1C3 (0.65) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 | |
| SCHEMBL2600793 | 1.00 | AKR1C3 (0.65) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL11722197 | 0.98 | AKR1C3 (0.63) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 | |
| SCHEMBL11459076 | 0.95 | AKR1C3 (0.58) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 | |
| SCHEMBL17369634 | 0.89 | AKR1C3 (0.53) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 | |
| SCHEMBL15695568 | 0.89 | AKR1C3 (0.53) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 | |
| SCHEMBL27634477 | 0.87 | CYP1A2 (0.50) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 | |
| SCHEMBL11470486 | 0.85 | AKR1C3 (0.69) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 | |
| SCHEMBL11721635 | 0.84 | CYP1A2 (0.46) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 | |
| SCHEMBL14983577 | 0.84 | CYP1A2 (0.46) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260124-A1 | NO- AND H2S- RELEASING COMPOUNDS | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK | 2017-09-14 | — | — | US | disclosed |
| US-9688607-B2 | No- and H2S-releasing compounds | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170143836-A1 | UNIQUE DUAL-ACTION THERAPEUTICS | LEHIGH UNIVERSITY | 2017-05-25 | — | — | US | disclosed |
| US-20160296623-A1 | HYDROGEL POLYMERIC COMPOSITIONS AND METHODS | INCEPT, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160200752-A1 | COX-2-TARGETING, PLATINUM-CONTAINING CONJUGATES AND THEIR USE IN THE TREATMENT OF TUMORS AND CANCERS | Reiley Pharmaceuticals, Inc. | 2016-07-14 | — | — | US | disclosed |
| US-9370485-B2 | Hydrogel polymeric compositions and methods | INCEPT, LLC (US) | 2016-06-21 | — | — | US | disclosed |
| US-20150239889-A1 | PYRAZOLOPYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-27 | — | — | US | disclosed |
| US-8921591-B2 | Process for synthesizing phenylacetic acid by carbonylation of toluene | LANZHOU INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2014-12-30 | — | — | US | disclosed |
| US-20140363498-A1 | HYDROGEL POLYMERIC COMPOSITIONS AND METHODS | INCEPT LLC | 2014-12-11 | — | — | US | disclosed |
| US-20140221316-A1 | NO- AND H2S- RELEASING COMPOUNDS | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130303798-A1 | PROCESS FOR SYNTHESIZING PHENYLACETIC ACID BY CARBONYLATION OF TOLUENE | LANZHOU INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2013-11-14 | — | — | US | disclosed |
| US-8563027-B2 | Drug delivery through hydrogel plugs | INCEPT, LLC (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130172268-A1 | DRUG DELIVERY THROUGH HYDROGEL PLUGS | INCEPT, LLC (US) | 2013-07-04 | — | — | US | disclosed |
| US-8303978-B2 | Controlled release of nitric oxide and drugs from functionalized macromers and oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120035259-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | BEZWADA BIOCHEMICAL, LLC (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120010168-A1 | Unique Dual-Action Therapeutics | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-01-12 | — | — | US | disclosed |
| US-20070281028-A1 | Drug Delivery of a Cox Inhibitor from Embolic Agents | BIOCOMPATIBLES UK LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20070281028-A1 | Drug Delivery of a Cox Inhibitor from Embolic Agents | BIOCOMPATIBLES UK LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| US-4048330-A | Compositions containing 2-(6'-substituted-2'-naphthyl)acetic acid esters used for treating inflammation, pain or pyrexia | SYNTEX CORPORATION (US) | 1977-09-13 | — | — | US | disclosed |
| US-3958012-A | ANTIINFLAMMATORY, ANALGESIC AND ANTIPYRETIC ACTIVITY | SYNTEX CORPORATION (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140363498-A1 | HYDROGEL POLYMERIC COMPOSITIONS AND METHODS | UACA, CRYAA, CRYAB | AKR1C3 3813/4885AKR1C2 3765/4885PTGS2 326/4885 |
| US-20140221316-A1 | NO- AND H2S- RELEASING COMPOUNDS | PTGS1, NOS2, NOS1 | AKR1C3 2456/4885AKR1C2 2270/4885PTGS2 4/4885 |
| US-20160200752-A1 | COX-2-TARGETING, PLATINUM-CONTAINING CONJUGATES AND THEIR USE IN THE TREATMENT OF TUMORS AND CANCERS | PTGS2, PTGES2, TOP2A | AKR1C3 2396/4885AKR1C2 2250/4885PTGS2 1/4885 |
| US-20120010168-A1 | Unique Dual-Action Therapeutics | ACHE, PDE1A, PDE1C | AKR1C3 217/4885AKR1C2 273/4885PTGS2 17/4885 |
| US-20170260124-A1 | NO- AND H2S- RELEASING COMPOUNDS | NOS2, NOS3, NOS1 | AKR1C3 2812/4885AKR1C2 2722/4885PTGS2 9/4885 |
| US-20170143836-A1 | UNIQUE DUAL-ACTION THERAPEUTICS | ACHE, PDE1A, PDE1C | AKR1C3 217/4885AKR1C2 273/4885PTGS2 17/4885 |
| US-20120035259-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | NOS2, NOS1, NOS3 | AKR1C3 314/4885AKR1C2 333/4885PTGS2 59/4885 |
| US-20160296623-A1 | HYDROGEL POLYMERIC COMPOSITIONS AND METHODS | CRYAA, CRYAB, UACA | AKR1C3 4118/4885AKR1C2 3900/4885PTGS2 253/4885 |
| US-20130303798-A1 | PROCESS FOR SYNTHESIZING PHENYLACETIC ACID BY CARBONYLATION OF TOLUENE | DDT, HPD, PAH | AKR1C3 440/4885AKR1C2 921/4885PTGS2 1236/4885 |
| US-20150239889-A1 | PYRAZOLOPYRIMIDINE COMPOUND | HIF1AN, EGLN2, EGLN3 | AKR1C3 1349/4885AKR1C2 662/4885PTGS2 585/4885 |
| US-20130172268-A1 | DRUG DELIVERY THROUGH HYDROGEL PLUGS | AQP1, AQP4, AQP3 | AKR1C3 4604/4885AKR1C2 4730/4885PTGS2 366/4885 |
| US-20070281028-A1 | Drug Delivery of a Cox Inhibitor from Embolic Agents | PTGER1, PTGS1, PTGES | AKR1C3 2518/4885AKR1C2 1913/4885PTGS2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.